We are live on ! Find out more
NRIX icon

Nurix Therapeutics
NRIX

139 hedge funds and large institutions have $721M invested in Nurix Therapeutics in 2024 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 41 increasing their positions, 45 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

68% more call options, than puts

Call options by funds: $564K | Put options by funds: $335K

65% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 17

42% more capital invested

Capital invested by funds: $508M → $721M (+$213M)

7% more funds holding

Funds holding: 130 → 139 (+9)

9% less repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 45

1.07% less ownership

Funds ownership: 101.47% → 100.4% (-1.1%)

Holders
139
Holders Change
+9
Holders Change %
+6.92%
% of All Funds
2%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
28
Increased
41
Reduced
45
Closed
17
Calls
$564K
Puts
$335K
Net Calls
+$229K
Net Calls Change
-$285K

Top Buyers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
+$19.4M
2
RG
Redmile Group
California
+$13.2M
3
Deutsche Bank
Deutsche Bank
Germany
+$10.7M
4
SCM
Soleus Capital Management
Connecticut
+$10.5M
5
IC
Ikarian Capital
Texas
+$3.23M

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$40.2M
2
WA
Wasatch Advisors
Utah
-$16.3M
3
BCLSI
Bain Capital Life Sciences Investors
Massachusetts
-$7.43M
4
TCM
TCG Crossover Management
California
-$7.41M
5
AIM
ARK Investment Management
Florida
-$6.02M
Name Holding Trade Value Shares
Change 		Change in
Stake
ACH
26
ArrowMark Colorado Holdings
Colorado
$4.63M – – –
Invesco
27
Invesco
Georgia
$4.6M +$2.82M +262,085 +516%
IC
28
Ikarian Capital
Texas
$4.41M +$3.23M +300,000 New
WFA
29
WestHill Financial Advisors
California
$4.16M – – –
Primecap Management
30
Primecap Management
California
$4.1M +$3M +279,000 New
OM
31
Opaleye Management
Massachusetts
$3.93M +$2.87M +267,210 New
SSA
32
Schonfeld Strategic Advisors
New York
$3.85M +$2.82M +262,162 New
PHP
33
Parkman Healthcare Partners
Connecticut
$3.67M +$2.69M +250,000 New
Connor, Clark & Lunn Investment Management (CC&L)
34
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$3.49M +$560K +52,034 +28%
Wellington Management Group
35
Wellington Management Group
Massachusetts
$3.43M +$299K +27,812 +14%
Citadel Advisors
36
Citadel Advisors
Florida
$3.16M +$1.97M +182,847 +574%
TI
37
Trexquant Investment
Connecticut
$3.13M +$576K +53,561 +34%
Rafferty Asset Management
38
Rafferty Asset Management
New York
$3.11M +$2.27M +211,425 New
Two Sigma Investments
39
Two Sigma Investments
New York
$3.11M +$1.25M +116,544 +123%
Arrowstreet Capital
40
Arrowstreet Capital
Massachusetts
$2.76M -$79.5K -7,393 -4%
Citigroup
41
Citigroup
New York
$2.72M +$1.82M +169,635 +1,120%
Norges Bank
42
Norges Bank
Norway
$2.66M -$835K -77,600 -30%
Renaissance Technologies
43
Renaissance Technologies
New York
$2.64M +$689K +64,100 +56%
Two Sigma Advisers
44
Two Sigma Advisers
New York
$2.62M +$1.6M +148,800 +511%
UBS Group
45
UBS Group
Switzerland
$2.48M +$995K +92,540 +121%
ECM
46
ExodusPoint Capital Management
New York
$2.43M -$1.42M -132,166 -44%
Acadian Asset Management
47
Acadian Asset Management
Massachusetts
$2.35M +$1.47M +136,606 +577%
Bank of New York Mellon
48
Bank of New York Mellon
New York
$2.34M -$149K -13,859 -8%
SPS
49
Susquehanna Portfolio Strategies
Pennsylvania
$2.33M – – –
Massachusetts Financial Services
50
Massachusetts Financial Services
Massachusetts
$1.66M -$316K -29,367 -21%
1
2
3 4 5

NRIX Hedge Fund Activity: Q1 2024 in Review

139 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Nurix Therapeutics (NRIX) for Q1 2024, worth a combined $721M — up 42% from $508M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new NRIX positions and 17 closed out — a net gain of 11 holders — while 41 added to existing stakes and 45 trimmed.

The largest buyer was State Street, adding an estimated $19.4M. The largest seller was Morgan Stanley, cutting an estimated $40.2M.

  • 139 institutional investors held Nurix Therapeutics (NRIX) as of Q1 2024, up from 130 in Q4 2023.
  • Funds reported $721M of Nurix Therapeutics stock for Q1 2024, up 42% quarter-over-quarter.
  • 28 funds opened new Nurix Therapeutics positions in Q1 2024 and 17 closed out, a net change of +11 holders.
  • The largest Nurix Therapeutics buyer in Q1 2024 was State Street, an estimated $19.4M added.
  • The largest Nurix Therapeutics seller in Q1 2024 was Morgan Stanley, an estimated $40.2M sold.

Based on aggregated 13F filings for Q1 2024.